Home › Research › Treatments
Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Poul F Høilund-Carlsen, Abass Alavi, Rudolph J Castellani, Rachael L Neve, George Perry, Mona-Elisabeth Revheim, Jorge R Barrio. International journal of molecular sciences, 2024-03-31
Topic: Drug trials: efficacy and safety
Plain-language summary
The amyloid cascade hypothesis for Alzheimer's disease is still alive, although heavily challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis' claim that the protein amyloid-beta is the cause of the disease. Two antibodies, aducanumab and lecanemab, have been approved by the U.S. Food and Drug Administration, while a third, donanemab, is under review. The main argument for the FDA approvals is a presumed therapy-induced removal of cerebral amyloid deposits. Lecanemab and donanemab are also thought to cause some statistical delay in the determination of cognitive decline. However, clinical efficacy that is less than with conventional treatment, selection of amyloid-positive trial patients with non-specific amyloid-PET imaging, and uncertain therapy-induced removal of cerebral amyloids in clinical trials cast doubt on this anti-Alzheimer's antibody therapy and hence on the amyloid hypothesis, calling for a more thorough investigation of the negative impact of this type of therapy on the brain.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Høilund-Carlsen, P. F., Alavi, A., Castellani, R. J., Neve, R. L., Perry, G., Revheim, M.-E., et al. (2024). Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers? International journal of molecular sciences. https://doi.org/10.3390/ijms25073892
Vancouver
Høilund-Carlsen PF, Alavi A, Castellani RJ, Neve RL, Perry G, Revheim M.-E, et al. Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers? International journal of molecular sciences. 2024. doi:10.3390/ijms25073892. PMID: 38612701.
BibTeX
@article{hoilundcarlsen2024-38612701,
author = {Høilund-Carlsen, Poul F and Alavi, Abass and Castellani, Rudolph J and Neve, Rachael L and Perry, George and Revheim, Mona-Elisabeth and Barrio, Jorge R},
title = {{Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?}},
journal = {International journal of molecular sciences},
year = {2024},
doi = {10.3390/ijms25073892},
pmid = {38612701},
url = {https://doi.org/10.3390/ijms25073892}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Two antibodies, aducanumab and lecanemab, have been approved by the U.S.
- Food and Drug Administration, while a third, donanemab, is under review.
- The main argument for the FDA approvals is a presumed therapy-induced removal of cerebral amyloid deposits.
- Lecanemab and donanemab are also thought to cause some statistical delay in the determination of cognitive decline.
- However, clinical efficacy that is less than with conventional treatment, selection of amyloid-positive trial patients with non-specific amyloid-PET imaging, and uncertain therapy-induced removal of cerebral amyloids in clinical trials cast doubt on this anti-Alzheimer's antibody therapy and hence on the amyloid hypothesis, calling for a more thorough investigation of the negative impact of this type of therapy on the brain.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 24 of the 56 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International journal of molecular sciences) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38612701) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 24 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 24 of the 56 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.